

# Medical Microbiology Advances and Infection Control

Patient Safety Dubai 2019

Stefan Weber, MD, MS, CIC

October 25, 2019


# No disclosures

# Objectives

- Explain the benefit of rapid microbiological diagnostic
- Summarize the value for Infection Control
- Know what are the challenges in the future



## Timeline



# The Role in Infection

- Surveillance
- Outbreak Detection
- Antibiotic Stewardship

# Microbiology is Part of the Team now...




# Surveillance

# The Challenge


- Multi-Drug Resistant Organisms need to be detected
- Rapid identification of quickly spreading diseases

# MDRO Detection

- Screening with chromogenic media
- Detection time: 24 hrs






MRSA



ESBL

# Rapid Antigen Detection

- Strep A
- RSV
- Influenza
- Malaria
- H.pylori
- C.Diff
- E.coli Toxin




# *Antigen tests*

**Table 3 -** Sensitivity, specificity, positive and negative predictive values and posite and negative LR for the medical opinion (physician) and the rapid test, considering the culture result as the diagnostic definition


	Sensitivity	Specificity	Predictive value		LR	
			Positive	Negative	Positive	Negative
Physician	79.3	53.2	35.43	88.8	1.7	0.4
Rapid test	96.7	94.4	84.8	98.9	17.2	0.03

LR = likelihood ratio.

# Rapid Antigen Test and Influenza Season



# Rapid Antigen Test and Influenza Season



# Keep in mind:

- Rapid antigen test support Clinical Decision Making
- The should always be confirmed by a reference method.

# Miniaturized PCR

- No need for multiple rooms
- Staff can be trained easily
- Performance: Sensitivity > 95%, Specificity>99%
- Higher costs compared to culture
- Directly from patient sample
- Performance time: 45 – 150 min




### Detection of

- MRSA
- MTb
- Enterovirus
- Influenza / RSV
- CT/NG
- Group-B Strep
- Carbapenemases
- 
-

# Carbapenemase Detection

- KPC
- NDM
- OXA-48
- VIM
- OXA-23 Gruppe
- OXA-40 Gruppe
- **OXA-58 Gruppe**




- KPC
- NDM
- OXA-48
- VIM
- OXA-23 Gruppe
- OXA-40 Gruppe
- **OXA-181**

Runtime: ~ 20 min

# Syndromic Testing (more than 10 reactions)

- Meningitis
- Respiratory Diseases
- Gastro-intestinal Diseases
- Blood Cultures
- Easy to train staff
- Runtime: ~ 60 min
- Infection Control
  - Decision support when to end isolation



- Meningitis

- *Escherichia coli* K1
- *Haemophilus influenzae*
- *Listeria monocytogenes*
- *Neisseria meningitidis*
- *Streptococcus agalactiae*
- *Streptococcus pneumoniae*
- Cytomegalovirus (CMV)
- Enterovirus (EV)
- Herpes simplex virus 1 (HSV-1)
- Herpes simplex virus 2 (HSV-2)
- Human herpesvirus 6 (HHV-6)
- Human parechovirus (HPeV)
- Varicella zoster virus (VZV)
- *Cryptococcus neoformans/gattii*


- Respiratory Disease

- Adenovirus
- Human Coronavirus (incl. MERS!)
- Human Metapneumovirus
- Human Rhinovirus/Enterovirus
- Influenza A
- Influenza A/H1, H#
- Influenza B
- Parainfluenza Virus 1-4
- Respiratory Syncytial Virus
- *Bordetella parapertussis*\*
- *Bordetella pertussis*
- *Chlamydia pneumoniae*
- *Mycoplasma pneumoniae*

# Outbreak Detection

- Rapid Detection
  - Unusual susceptibilities
  - Unusual strains
  - Unusual numbers (above the seasonal endemic rate)
- Cluster Detection
  - SaTScan Software (integrated in WHOnet)
  - Retrospective and real time
  - Integrated software in HIS
- Clonal Identification

# Pulsed Field Gel Electrophoresis (PFGE)



.... Long Turn-Around-Time ... (3-4 days)



# Next Generation / Whole Genome Sequencing


- Future method for identification, typing and susceptibility testing
- New instruments and software tools
- Applicability for diagnostic laboratories
- Minion technology
- Time to whole sequence for bacterial genome
  - 1 day in Illumina
  - 3-5 hours





DROP FILE HERE TO ANALYSE

BROWSE...



A large, semi-transparent circular progress bar is centered on the screen. The circle is divided into two main segments: a light gray segment at the top and a white segment below it. The white segment contains the text "38%" in a large, light gray font. Below this, the text "CONSTRUCTING GENOME" is displayed in a smaller, gray font. The entire progress bar is set against a background of abstract, overlapping shapes in orange and blue.

38%

CANCEL

MYKROBE  
PREDICTOR  
TB

VIEW ALL DRUGS

SPECIES

EVIDENCE

SAVE NEW



SPECIES

M. tuberculosis (lineage: Beijing/East Asia)



VIEW ALL

DRUGS

SPECIES

EVIDENCE

SAVE

NEW



SUSCEPTIBLE

Ethambutol  
Quinolones



RESISTANT

Isoniazid  
Rifampicin  
Streptomycin  
Amikacin  
Capreomycin  
Kanamycin



VIEW ALL

DRUGS

SPECIES

EVIDENCE

SAVE NEW

1

## FIRST LINE DRUGS

- Isoniazid ▲
- Rifampicin ▲
- Ethambutol ●

2

## SECOND LINE DRUGS

- Quinolones ●
- Streptomycin ▲
- Amikacin ▲
- Capreomycin ▲
- Kanamycin ▲


R

## RESISTANCE

Extensively Drug Resistant (XDR)

# Antibiotic Stewardship

# Susceptibility of Selected PICU Respiratory Pathogens 2018



# Summary and Recommendations

- Carbapenem resistance is still a concern, but numbers remain stable
- ICUs with high resistance rate should not use a Carbapenem as empiric therapy any more
- For *Pseudomonas aeruginosa*, Meropenem is no longer an option for empiric therapy.
- *S.maltophilia* high in ward X respiratory samples
- Low Acinetobacter incidence

# Conclusion

- Infection Control and Microbiology are integral parts of safe patient care now
- They make important contributions to the Antimicrobial Stewardship Program
- Rapid diagnostic methods improve the decision making
- Sequencing method will improve outbreak control and prevention

# Gram-Negatives 2018

## Adult Population

Species (N)	Amp	Am/Cla	Pip/Taz	CXM	CTX	CAZ	CPM	GEN	TOB	AMK	MER	ERTA	SXT	CIP	Fosfo	Nitro	Tig/Min
<b>E.Coli (937)</b>	30.6	51.6	90.1			63.1	63.5	83.3		98.4	99.7	99.1	52.7	54.4	98.4	91.3	100
<b>Pseudomonas aeruginosa (414)</b>			95.2			89.0	89.0		96.1	96.4	81.3			89.0			
<b>Klebsiella pneumoniae (507)</b>	0	67.8	83.2			71.8	72.3	89.1		98.3	97.5	95.6	74.3	82.8	84.2	31.6	100
<b>Stenotroph. maltophilia (103)</b>						64.7					0		85.0	47.1			96.1
<b>Enterobacter cloacae (63)</b>	0	0	79.3			72.4	89.7	91.4		98.3	98.3	96.6	81.0	93.1	63.8	39.7	50.0
<b>Serratia marcescens (83)</b>	0	0	89.6			82.9	91.4	91.4		100	97.1	94.3	91.4	94.3	97.1	0	
<b>Proteus mirabilis (91)</b>	63.1	93.7	100			90.5	90.5	77.4		95.2	100	98.8	52.4	67.9	86.9	0	0
<b>Acinetobact. Baumannii (70)</b>		12.5 (Amp/ Sul)	62.5			60.4	68.8	79.2	83.3		70.8		89.6	64.6			87.5
<b>Haemophilus influenza (56)</b>	91.1	100		96.4	100								62.5	94.6			

# References

- Diekema, D., Saubolle, M.A. Clinical Microbiology and Infection Prevention. 2011. *J Clin Mic.* 49 (9) Suppl., Sept 2011: S57-S60.
- Pfaller, M.A., Herwaldt, L.A. The Clinical Microbiology Laboratory and Infection Control: Emerging Pathogens, Antimicrobial Resistance, and New Technology. 1997. *Clin Inf Dis Vol.* 25 (4): 858-870.
- Dangel, A. et al. Genetic diversity and delineation of *Salmonella* Agona outbreak strains by next generation sequencing, Bavaria, Germany, 1993 to 2018. 2019. *Eurosurveillance* 24 (18):



## Sheikh Khalifa Medical City and Pathology and Laboratory Institute



80050

www.seha.ae



MORE QUESTIONS?  
MORE QUESTIONS?

**Thank you!**